HitGen’s 2025 H1 Report Shows 16.58% Revenue Growth and 391% Profit Surge
Others

HitGen’s 2025 H1 Report Shows 16.58% Revenue Growth and 391% Profit Surge

Changchun High Files GenSci134 Clinical Trial for Growth Hormone Deficiency
CompanyDrug

Changchun High Files GenSci134 Clinical Trial for Growth Hormone Deficiency

Fosun Pharma Grants Sitala Global License for FXS6837 – Up to $190 M Milestones
CompanyDeals

Fosun Pharma Grants Sitala Global License for FXS6837 – Up to $190 M Milestones

Regeneron’s Cemdisiran Beats Key Milestones in Phase III gMG Trial
CompanyDrug

Regeneron’s Cemdisiran Beats Key Milestones in Phase III gMG Trial

Gilead’s Yeytuo Gains EU Marketing Authorization for Twice‑Yearly HIV‑1 PrEP
CompanyDrug

Gilead’s Yeytuo Gains EU Marketing Authorization for Twice‑Yearly HIV‑1 PrEP

TYK Medicines Secures Exclusive Distribution of TY‑9591 in Mainland China
CompanyDeals

TYK Medicines Secures Exclusive Distribution of TY‑9591 in Mainland China

Fosun Pharma Reports 4.6% Revenue Decline in 2025 H1 – Innovative Drugs Drive Growth
Company

Fosun Pharma Reports 4.6% Revenue Decline in 2025 H1 – Innovative Drugs Drive Growth

C‑MER Announces Acquisition of Hong Kong Endoscopy Centre
CompanyDeals

C‑MER Announces Acquisition of Hong Kong Endoscopy Centre

Junshi Biosciences Reports 49% Revenue Growth in H1 2025
Company

Junshi Biosciences Reports 49% Revenue Growth in H1 2025

Innogen Commences Phase II Trial of Efsubaglutide Alfa for Obesity in Australia
CompanyDrug

Innogen Commences Phase II Trial of Efsubaglutide Alfa for Obesity in Australia

Humanwell Secures NMPA Approval for Remimazolam ICU Sedation
CompanyDrug

Humanwell Secures NMPA Approval for Remimazolam ICU Sedation

Eisai & Biogen Launch Lecanemab in Austria & Germany – First Cause‑Based Alzheimer’s Therapy
CompanyDrug

Eisai & Biogen Launch Lecanemab in Austria & Germany – First Cause‑Based Alzheimer’s Therapy